Contrasting Yarrow Bioscience (NASDAQ:YARW) and Pharming Group (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Profitability

This table compares Pharming Group and Yarrow Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharming Group	6.23%	8.70%	4.93%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Valuation and Earnings

This table compares Pharming Group and Yarrow Bioscience”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13 million	2.45	$2.85 million	$0.32	40.73
Yarrow Bioscience	$570,000.00	83.16	-$26.48 million	($14.64)	-1.21

Pharming Group has higher revenue and earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Pharming Group and Yarrow Bioscience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1	1	3	0	2.40
Yarrow Bioscience	1	0	3	0	2.50

Pharming Group presently has a consensus price target of $39.67, suggesting a potential upside of 204.31%. Yarrow Bioscience has a consensus price target of $59.00, suggesting a potential upside of 232.34%. Given Yarrow Bioscience’s stronger consensus rating and higher possible upside, analysts plainly believe Yarrow Bioscience is more favorable than Pharming Group.

Volatility & Risk

Pharming Group has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Comparatively, Yarrow Bioscience has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.

Insider & Institutional Ownership

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Pharming Group beats Yarrow Bioscience on 7 of the 13 factors compared between the two stocks.

About Pharming Group

Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.